Researchers from Eli Lilly are set to present new findings on Alzheimer’s disease diagnostics and treatments at the upcoming AAIC 2026 conference. Among the highlights is data on the P-tau217 blood test, which shows promise in diagnosing Alzheimer’s earlier than traditional methods. The research also includes insights from long-term studies on Kisunla (donanemab-azbt), an amyloid-targeting treatment that aims to slow the progression of the disease in individuals with mild cognitive impairment and early-stage dementia.

This matters because early detection and intervention could significantly impact the lives of millions. By 2030, an estimated 78 million people are projected to have Alzheimer’s, and many express a desire to know their status before symptoms interfere with daily life. The P-tau217 test could help identify those at risk, allowing for earlier treatment options that may preserve memory and cognitive function. For individuals concerned about Alzheimer’s, understanding these advancements could empower them to take proactive steps in managing their health.

The research presented at AAIC 2026 will include a mix of diagnostic and treatment studies, showcasing the evolving landscape of Alzheimer’s care. While the findings are promising, they represent an early stage in the ongoing battle against Alzheimer’s, with much still to be validated in larger human trials. Kisunla has already been approved for certain patients, but its long-term effects and the best practices for its use are still being explored.

If you’re concerned about Alzheimer’s, consider discussing the latest diagnostic options with your healthcare provider. They can help you understand your risk factors and the potential benefits of early testing and treatment.

SOURCE: Eli Lilly and Company